Spots Global Cancer Trial Database for quantitative susceptibility mapping
Every month we try and update this database with for quantitative susceptibility mapping cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial | NCT02603328 | Cerebral Cavern... | Atorvastatin Placebo | 18 Years - 80 Years | University of Chicago | |
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). | NCT05961644 | Multiple Sclero... Multiple Sclero... | Cladribine Subc... 0.9% Chloride I... | 30 Years - 65 Years | Institute of Psychiatry and Neurology, Warsaw | |
Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial | NCT02603328 | Cerebral Cavern... | Atorvastatin Placebo | 18 Years - 80 Years | University of Chicago | |
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). | NCT05961644 | Multiple Sclero... Multiple Sclero... | Cladribine Subc... 0.9% Chloride I... | 30 Years - 65 Years | Institute of Psychiatry and Neurology, Warsaw |